Blackstone Inc
ACRS icon

Blackstone Inc’s Aclaris Therapeutics ACRS Stock Holding History

Blackstone Inc’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,033
Closed -$16.2K – 175
2024
Q1 		$16.2K Hold
13,033
– – ﹤0.01% 174
2023
Q4 		$13.7K Sell
13,033
-1,248,392
-99% -$3.81M ﹤0.01% 159
2023
Q3 		$8.64M Buy
1,261,425
+1,248,392
+9,579% +$10.7M 0.04% 83
2023
Q2 		$135K Hold
13,033
– – ﹤0.01% 147
2023
Q1 		$105K Hold
13,033
– – ﹤0.01% 157
2022
Q4 		$205K Hold
13,033
– – ﹤0.01% 154
2022
Q3 		$205K Hold
13,033
– – ﹤0.01% 193
2022
Q2 		$182K Hold
13,033
– – ﹤0.01% 222
2022
Q1 		$225K Hold
13,033
– – ﹤0.01% 214
2021
Q4 		$189K Buy
+13,033
New +$197K ﹤0.01% 392

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Blackstone Inc's ACRS Position: Q2 2024 in Review

Blackstone Inc sold out of Aclaris Therapeutics (ACRS) in Q2 2024, closing a stake of 13,033 shares — an estimated $16.2K sold.

Blackstone Inc first reported a position in ACRS in Q4 2021 and held it in 10 quarters. The position peaked at $8.64M in Q3 2023. 98 funds tracked by Wall St. Rank hold ACRS as of Q2 2024.

  • Blackstone Inc reported no remaining Aclaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Blackstone Inc sold 13,033 Aclaris Therapeutics shares in Q2 2024, an estimated $16.2K.
  • Blackstone Inc first reported a position in Aclaris Therapeutics in Q4 2021 and held it in 10 quarters.
  • Blackstone Inc's Aclaris Therapeutics position peaked at $8.64M in Q3 2023.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2024.

Based on Blackstone Inc's 13F filing for Q2 2024, filed 14 Aug 2024.